The promise and peril of surrogate end points in cancer research.

Area of Science:

• Oncology
• Clinical Trials
• Biostatistics

Background:

• Cancer research traditionally relies on incidence, recurrence, or death as study endpoints.
• These traditional endpoints often necessitate large patient cohorts and lengthy follow-up periods.
• Surrogate endpoints offer a potentially faster and more efficient alternative for evaluating cancer interventions.

Purpose of the Study:

• To explore the utility and challenges of using surrogate endpoints in cancer research.
• To critically assess the validity of surrogate endpoints in predicting true clinical outcomes.
• To discuss the implications of surrogate endpoints for the design and interpretation of cancer studies.

Main Methods:

• Review of traditional endpoint methodologies in etiological, prevention, and therapeutic cancer studies.
• Discussion of the characteristics and potential benefits of surrogate endpoints.
• Analysis of the criteria and validation processes required for reliable surrogate endpoints.

Main Results:

• Traditional endpoints like cancer incidence, recurrence, or death are often impractical due to cancer's long latency and rarity.
• Surrogate endpoints, such as preclinical markers or indicators of imminent recurrence, present an attractive alternative.
• Ensuring the validity of surrogate endpoints is crucial for their reliable application in clinical research.

Conclusions:

• Surrogate endpoints can expedite cancer research by providing earlier insights into treatment efficacy.
• Rigorous validation is essential to confirm that surrogate endpoints accurately predict definitive clinical outcomes.
• The judicious use of validated surrogate endpoints can enhance the efficiency of cancer studies while maintaining scientific integrity.